Apollomics Doses First Patient in a Phase 1 Clinical Trial of APL-102
Apollomics Inc. recently announced the successful dosing of the first patient in a Phase 1 clinical study of APL-102 in patients with advanced solid tumors. The Phase 1 trial is designed to assess the safety, tolerability, and pharmacokinetics of APL-102 delivered via an oral capsule.
“APL-102 is an internally discovered and developed tyrosine kinase inhibitor targeting multiple oncogenic drivers, and we are excited about advancing it for clinical testing to explore its potential for treating a number of solid tumors,” said Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer. “APL-102 is the first of several novel assets planned for clinical development to further expand Apollomics’ clinical pipeline in oncology.”
APL-102 is an oral, small molecule multi kinase inhibitor (MTKi) targeting several key oncogenic drivers. APL-102 inhibits several receptor tyrosine kinases (RTKs), including: angiogenesis via vascular endothelial growth factor receptors (VEGFRs), mitogen-activated protein kinase (MAPK) pathway via B-RAF and C-RAF; and colony stimulating factor 1 receptor (CSF1R).
Preclinical studies have demonstrated broad and potent antitumor activity in patient-derived xenograft mouse models of liver, breast, colorectal, gastric, esophageal, and lung cancers. APL-102 has also shown favorable preclinical pharmacokinetic (PK) and safety profiles with no serious off-target activity observed. APL-102 has the potential to be used as a single agent or in combination with other oncology agents. Apollomics retains worldwide rights to APL-102.
Apollomics Inc. is an innovative biopharmaceutical company committed to the discovery and development of monotherapies and combination therapies of tumor-targeting agents and immuno-oncology agents. The company’s product pipeline has several programs at different stages of development, including novel, humanized monoclonal antibodies that restore the body’s immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Apollomics has operating entities in Foster City, CA, Hangzhou and Shanghai, China. For more information, visit www.apollomicsinc.com.
Total Page Views: 773
